Is Vyne Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Vyne Therapeutics Inc (VYNE) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Vyne Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Vyne Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Vyne Therapeutics Inc?

Muslim investors may consider investing in Vyne Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Vyne Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Vyne Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Vyne Therapeutics Inc updated?

The Shariah compliance status of Vyne Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Vyne Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Vyne Therapeutics Inc?

You can check the latest Shariah compliance status of Vyne Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

VYNE Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 11, 2026

Report Source: 2025 Annual Report

Vyne Therapeutics Inc. Stock Analysis VYNE

United States Health Care Nano Cap Report: 2025 Annual

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. The company is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Key Statistics of Vyne Therapeutics Inc (VYNE)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.66$0.67

Today's Open

$0.67

Volume

106.40K

P/E Ratio (TTM)

52 Week Range

$0.28$1.96

Market Cap

22.20M

Avg. Volume

195.32K

Dividend Yield

Financial Metrics & Statements of Vyne Therapeutics Inc (VYNE)

FAQ's for Vyne Therapeutics Inc (VYNE)

According to Musaffa’s Shariah screening methodology, Vyne Therapeutics Inc (VYNE) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.